Aaron Bartlone - Cybin Chief Officer
| CYBN Stock | USD 10.64 0.82 8.35% |
Insider
Aaron Bartlone is Chief Officer of Cybin Inc
| Age | 57 |
| Address | 100 King Street West, Toronto, ON, Canada, M5X 1C9 |
| Phone | 908 764 8385 |
| Web | https://www.cybin.com |
Cybin Management Efficiency
The company has return on total asset (ROA) of (0.3271) % which means that it has lost $0.3271 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4907) %, meaning that it created substantial loss on money invested by shareholders. Cybin's management efficiency ratios could be used to measure how well Cybin manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.2. At this time, Cybin's Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 87.7 M, while Non Currrent Assets Other are likely to drop (292.2 K).Similar Executives
| Showing other executives | INSIDER Age | ||
| Florian Brand | ATAI Life Sciences | 37 | |
| JD MBA | Immix Biopharma | N/A | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| Matthew MBA | Iteos Therapeutics | 51 | |
| MD MA | Mind Medicine | 44 | |
| Gopal Krishna | Seelos Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Florian M | GH Research PLC | 55 | |
| Thomas Walker | Bio Path Holdings | N/A | |
| James Goding | Opthea | N/A | |
| Annie Lee | Opthea | N/A | |
| Michael Carruthers | Edgewise Therapeutics | 66 | |
| Alan Russell | Edgewise Therapeutics | 54 | |
| Magnus Halle | GH Research PLC | 27 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Peter MBA | Bio Path Holdings | 75 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.33 |
Cybin Inc Leadership Team
Elected by the shareholders, the Cybin's board of directors comprises two types of representatives: Cybin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cybin. The board's role is to monitor Cybin's management team and ensure that shareholders' interests are well served. Cybin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cybin's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alex Nivorozhkin, Chief Officer | ||
| Greg Cavers, Chief Officer | ||
| Gabriel Fahel, Chief Secretary | ||
| John Kanakis, CoFounder | ||
| Douglas Drysdale, Chief Officer | ||
| Erica Olson, VP Controller | ||
| Eric LLB, President CoFounder | ||
| George Tziras, Chief Director | ||
| Aaron Bartlone, Chief Officer | ||
| Lori Challenger, Ethics Compliance | ||
| Sara Somerset, Chief Officers | ||
| Paul Glavine, Chief CoFounder | ||
| MD DFAPA, Senior Development | ||
| Leah Gibson, VP Communications | ||
| LLB LLB, Pres CoFounder |
Cybin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cybin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 100.98 M | ||||
| Shares Outstanding | 19.99 M | ||||
| Shares Owned By Insiders | 6.34 % | ||||
| Shares Owned By Institutions | 36.60 % | ||||
| Number Of Shares Shorted | 609.73 K | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 278.25 X | ||||
| Gross Profit | (311 K) |
Pair Trading with Cybin
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cybin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cybin will appreciate offsetting losses from the drop in the long position's value.Moving against Cybin Stock
| 0.71 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.69 | NKTX | Nkarta Inc | PairCorr |
| 0.68 | ME | 23Andme Holding | PairCorr |
| 0.67 | TPST | Tempest Therapeutics | PairCorr |
| 0.63 | MTEM | Molecular Templates | PairCorr |
The ability to find closely correlated positions to Cybin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cybin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cybin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cybin Inc to buy it.
The correlation of Cybin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cybin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cybin Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cybin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cybin Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cybin. If investors know Cybin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cybin listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.14) | Return On Assets (0.33) | Return On Equity (0.49) |
The market value of Cybin Inc is measured differently than its book value, which is the value of Cybin that is recorded on the company's balance sheet. Investors also form their own opinion of Cybin's value that differs from its market value or its book value, called intrinsic value, which is Cybin's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cybin's market value can be influenced by many factors that don't directly affect Cybin's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cybin's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cybin is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cybin's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.